VJOncology is committed to improving our service to you

ASCO 2019 | IMpassion130: Implications

VJOncology is committed to improving our service to you

Peter Schmid

Peter Schmid, MD, PhD, FRCP, of the Barts Cancer Institute, London, UK, discusses the implications of the results gleaned form the IMpassion130 trial (NCT02425891). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter